Literature DB >> 30528418

Prevention of Diabetes Mellitus in Patients With Prediabetes.

Nicholas W Carris1, Ronald R Magness2, Arthur J Labovitz3.   

Abstract

Cardiovascular disease is a leading cause of death in patients with diabetes. Consequently, as antidiabetic medications have demonstrated cardiovascular benefit, cardiologists have been asked to weigh in regarding antidiabetic therapy. The cardiologist's role will continue to grow as antidiabetic agents with cardiovascular benefit are being studied in prediabetes as part of an evolving clinical environment. Still, current guidelines primarily recommend high-intensity lifestyle intervention or metformin for diabetes prevention. Considering that many patients cared for by a cardiologist will have prediabetes, we propose herein that cardiologists can also facilitate diabetes prevention through direct intervention, referring patients to community-based high-intensity lifestyle interventions, and through advocacy, policy, and additional guideline development. The most important messaging for a patient is that avoiding new-onset diabetes can reduce microvascular disease, reduce healthcare cost, and improve health-related quality of life. Moreover, as the mortality risk of patients with a history of myocardial infarction and diabetes is almost double that of patients with a history of myocardial infarction who are free of diabetes, there is even more potential benefit in delaying and/or avoiding diabetes in patients with cardiovascular disease. Despite these important health advantages, the implementation of diabetes prevention strategies is lagging. The under implementation may be exaggerated by published opinions conflicting major guidelines in addition to conflicting guideline recommendations. In conclusion, we propose cardiologists can play a key role in preventing diabetes and aligning practice patterns with guideline recommendations among endocrinology, cardiology, and primary care stake holders.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30528418      PMCID: PMC6350898          DOI: 10.1016/j.amjcard.2018.10.032

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  33 in total

1.  Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement.

Authors:  Albert L Siu
Journal:  Ann Intern Med       Date:  2015-10-27       Impact factor: 25.391

2.  Preventing new-onset diabetes in thiazide-treated patients.

Authors:  Giuseppe Mancia
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-18       Impact factor: 32.069

3.  Prediabetes Screening and Treatment in Diabetes Prevention: The Impact of Physician Attitudes.

Authors:  Arch G Mainous; Rebecca J Tanner; Christopher B Scuderi; Maribeth Porter; Peter J Carek
Journal:  J Am Board Fam Med       Date:  2016-11-12       Impact factor: 2.657

4.  What We Don't Talk About When We Talk About Preventing Type 2 Diabetes-Addressing Socioeconomic Disadvantage.

Authors:  Gabriela Spencer Bonilla; Rene Rodriguez-Gutierrez; Victor M Montori
Journal:  JAMA Intern Med       Date:  2016-08-01       Impact factor: 21.873

5.  Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2018; zzm321990Medicare Shared Savings Program Requirements; and Medicare Diabetes Prevention Program. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2017-11-15

6.  Metformin prescribing in low-income and insured patients with prediabetes.

Authors:  Jun Wu; Eileen Ward; Tiffaney Threatt; Zhiqiang K Lu
Journal:  J Am Pharm Assoc (2003)       Date:  2017-05-24

Review 7.  How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD.

Authors:  Kimberly N Hong; Valentin Fuster; Robert S Rosenson; Clive Rosendorff; Deepak L Bhatt
Journal:  J Am Coll Cardiol       Date:  2017-10-24       Impact factor: 24.094

8.  The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.

Authors: 
Journal:  Diabetes Care       Date:  2012-04       Impact factor: 19.112

Review 9.  Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.

Authors:  William T Cefalu; John B Buse; Jaakko Tuomilehto; G Alexander Fleming; Ele Ferrannini; Hertzel C Gerstein; Peter H Bennett; Ambady Ramachandran; Itamar Raz; Julio Rosenstock; Steven E Kahn
Journal:  Diabetes Care       Date:  2016-06-09       Impact factor: 19.112

10.  Metformin Use in Prediabetes Among U.S. Adults, 2005-2012.

Authors:  Eva Tseng; Hsin-Chieh Yeh; Nisa M Maruthur
Journal:  Diabetes Care       Date:  2017-04-03       Impact factor: 19.112

View more
  9 in total

Review 1.  Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.

Authors:  Fahadul Islam; Jannatul Fardous Khadija; Md Rezaul Islam; Sheikh Shohag; Saikat Mitra; Saad Alghamdi; Ahmad O Babalghith; Abdulrahman Theyab; Mohammad Tauhidur Rahman; Aklima Akter; Abdullah Al Mamun; Fahad A Alhumaydhi; Talha Bin Emran
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-21       Impact factor: 2.650

2.  Dietary Patterns and the Risk of Prediabetes in Taiwan: A Cross-Sectional Study.

Authors:  Yi-Cheng Hou; Han-Chih Feng; I-Shiang Tzeng; Chan-Yen Kuo; Ching-Feng Cheng; Jing Hui Wu; Shwu-Huey Yang
Journal:  Nutrients       Date:  2020-10-29       Impact factor: 5.717

3.  The predictive utility of circulating PCSK9 levels on diabetes mellitus.

Authors:  Jia Peng; Cheng-Gang Zhu; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2021-02-13       Impact factor: 9.951

4.  Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  Sci Rep       Date:  2021-04-30       Impact factor: 4.379

5.  Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein.

Authors:  Fei Gao; Dingying Wu; Lingling Guo; Lixue Wang; Min Hao; Ling Li; Dongmei Ni; Haojie Hao
Journal:  Ann Transl Med       Date:  2021-07

6.  Assessing the implementation of a clinical decision support tool in primary care for diabetes prevention: a qualitative interview study using the Consolidated Framework for Implementation Science.

Authors:  Rebekah Pratt; Daniel M Saman; Clayton Allen; Benjamin Crabtree; Kris Ohnsorg; JoAnn M Sperl-Hillen; Melissa Harry; Hilary Henzler-Buckingham; Patrick J O'Connor; Jay Desai
Journal:  BMC Med Inform Decis Mak       Date:  2022-01-15       Impact factor: 2.796

7.  Outcomes between prediabetes and type 2 diabetes mellitus in older adults with acute myocardial infarction in the era of newer-generation drug-eluting stents: a retrospective observational study.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Sang-Ho Park; Byung Gyu Kim; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  BMC Geriatr       Date:  2021-11-19       Impact factor: 3.921

8.  Antidiabetic Effects of Pediococcus acidilactici pA1c on HFD-Induced Mice.

Authors:  Miriam Cabello-Olmo; María Oneca; María José Pajares; Maddalen Jiménez; Josune Ayo; Ignacio J Encío; Miguel Barajas; Miriam Araña
Journal:  Nutrients       Date:  2022-02-07       Impact factor: 5.717

9.  Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  BMC Cardiovasc Disord       Date:  2021-08-09       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.